The landscape of treating Mucopolysaccharidosis Type I has experienced remarkable advancement, evolving from an era of limited therapeutic options to a sophisticated array of treatment modalities that target the disease at multiple levels. This rare lysosomal storage disorder, characterized by alpha-L-iduronidase deficiency, presents unique clinical challenges that have catalyzed...